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Abstract
Background The present study was aimed to evaluate the
usefulness of contrast Sonazoid-enhanced ultrasonography
(US) for the detection of hepatic metastases in breast
cancer patients and compare the clinical efficacy and sen-
sitivity of this technique with conventional contrast unen-
hanced B-mode US in follow-up examinations of breast
cancer patients with liver metastasis.
Methods We assessed a total of 84 hepatic tumors from
24 patients diagnosed with or suspected of having meta-
static cancer. These hepatic nodules were diagnosed
through imaging, including dynamic magnetic resonance
imaging (MRI), contrast-enhanced computed tomography
(CECT) scan, B-mode US or contrast Sonazoid-enhanced
US (SEUS). Differences in the sensitivity between US and
SEUS were compared using MR imaging, CECT, and
follow-up imaging.
Results A total of 79 nodules were diagnosed as meta-
static tumors. The remaining nodules were diagnosed as
benign tumors (hepatic hemangioma: n = 3; local fatty
change: n = 2). SEUS precisely detected the presence or
absence of hepatic tumors in the 24 patients examined,
showing a sensitivity of 98.8 % (83 of 84 lesions) for total
imaged solid liver lesions, with an accuracy of 98.7 % (78
of 79 lesions) for total metastatic breast cancer lesions. In
contrast, conventional B-mode US imaging revealed
hepatic tumor lesions at a sensitivity of 66.7 % (56 of 84
lesions) and an accuracy of 64.6 % (51 of 79 lesions),
respectively. Furthermore, the false positive and false
negative rates were, respectively, 6.33 and 29.1 % for
B-mode US and 0 and 1.3 % for SEUS. Moreover, twenty-
seven metastatic tumors and five benign lesions (3 he-
mangiomas and 2 focal fatty changes/sparings) were
imaged using SEUS but not conventional B-mode US.
Significant differences in diagnostic accuracy rates
between contrast Sonazoid-enhanced US and conventional
B-mode US were observed (Wilcoxon signed rank test:
p = 0.0009). No severe adverse events occurred during
SEUS after the administration of Sonazoid, except for a
grade 1 skin reaction and nausea in one patient.
Conclusion These results suggested that Sonazoid could
be safely administrated to breast cancer patients with liver
metastatic disease. Thus, contrast Sonazoid-enhanced US is
a feasible and more effective method than B-mode US for
the detection of hepatic metastasis, particularly for small
metastatic breast cancer lesions less than 14 mm in diam-
eter, showing significant high sensitivity and accuracy.
Keywords Breast cancer  Liver metastasis  B-mode
ultrasonography  Contrast Sonazoid-enhanced
ultrasonography
Introduction
Hepatic metastasis is a major problem in breast cancer
patients. The detection of these lesions has treatment and
prognostic implications, and accurate staging is also a
prerequisite for monitoring chemotherapy. Although an
abdominal liver ultrasound is not recommended for routine
breast cancer surveillance, as to other conventional exam-
inations, ultrasonography has been reported as effective for
the ‘‘early’’ detection of hepatic recurrences [1, 2]. Despite
the recent development of new techniques, including
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18-fluro-2-deoxyglucose (FDG) positron emission tomog-
raphy (PET) computed tomography (CT) and dynamic
magnetic resonance imaging (MRI), for the detection of
hepatic metastasis from breast cancer, the use of ultraso-
nography (US) for the assessment and follow-up of hepatic
metastatic disease might benefit from a reliable, easily
available, low cost, noninvasive imaging modality.
Although B-mode US is commonly performed as a
screening examination, most of the conventional US
techniques have relatively poor sensitivity and specificity
for imaging liver metastases (53–76 %), and trans-
abdominal US is inferior in sensitivity for liver metastases
compared with CT or MRI primarily reflecting a lack of
contrast agents. Currently CECT and MRI are the only
imaging modalities that offer the highest diagnostic
potential for the assessment of liver metastases in breast
cancer patients [3, 4].
Contrast-enhanced US has been demonstrated as a
suitable technique for the detection of hepatic malig-
nancy or metastases and is more accurate compared with
conventional B-mode US [5–9]. However, the efficacy of
contrast-enhanced US for the detection of hepatic
metastases from breast cancer has not been specifically
evaluated. Sonazoid (Diichi-Sankyo, Tokyo, Japan) is a
new microbubble agent that provides a parenchyma-
specific contrast image based on its accumulation in the
Kupffer cells of the liver [10–14]. Sonazoid has previ-
ously been approved for clinical use in Japan, and this
agent presents a image in the post-vascular phase (Ku-
pffer image) with a long duration, followed by the
images of the arterial phase and the portal phase (vas-
cular phase) [15, 16]. In the present clinical study, we
demonstrate the use of Sonazoid in contrast-enhanced




Between September 2011 and December 2012, 24 female
patients (median age 59 years, range 41–72 years) with
histologically diagnosed metastatic breast cancer were
included in this study. Inclusion criteria were referral to the
radiology department for CECT and/or US of the liver for
suspected or known hepatic metastases. In addition to the
hepatic metastases from primary breast cancer, the other
metastatic sites included bone (n = 17), lung (n = 8),
distant lymph nodes (n = 5), brain (n = 3) and skin–chest
wall recurrence (n = 2). The median number of sites of
metastatic disease before the entry was 3 (range 1–5sites).
All patients with metastatic disease were treated with
conventional chemotherapy and/or endocrine therapy using
weekly paclitaxel with trastuzumab for 3 patients, tri-
weekly docetaxel with trastuzumab for 4 patients, Eribulin
for 2 patients and Capecitabine for 1 patient. The remain-
ing 14 patients underwent endocrine therapy, including
Tamoxifen for 4 patients and aromatase inhibitor for 10
patients (anastrozoles for 5 patients, letrozoles for 3
patients, and exemestanes for 2 patients). In addition, 3
patients with Her-2 positive metastatic disease also
underwent concurrent trastuzumab treatment (Table 1). All
patients provided written informed consent for participa-
tion in this study.
Table 1 Characteristics of the patients with suspected hepatic
metastases and adverse events during SEUS
Characteristics a No. Percentage
Age (median) 59 years old
(41–72)
Menopausal status
Premenopause 4 17 %
Postmenopause 20 83 %
Intrinsic subtype
Luminal phenotype 9 38 %
HER2 phenotype 9 38 %
Triple negative phenotype 6 25 %
Sites of metastases beside liver
Bone 17
Lung 8
Distant lymph nodes 5
Brain 3
Skin-chest wall recurrence 2
Treatmentb
Chemotherapy (? trastuzumab) 10 (6) 42 %
Endocrine therapy
(? trastuzumab)
14 (3) 58 %








a The median follow-up time was 14.1 months (range 9–28 months)
b The treatment for metastatic disease included chemotherapy with
trastuzumab for 6 patients (3 patients were treated weekly with
Paclitaxel and 4 patients were treated triweekly with docetaxel),
endocrine therapy with trastuzumab for 3 patients, Eribulin was
administered to 2 patients and Capecitabine was used to treat 1
patient. The remaining eleven patients underwent endocrine therapy
only
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Imaging techniques, equipments and imaging
assessment
All patients underwent conventional US, contrast Sona-
zoid-enhanced US (SEUS), and CECT or MRI. The
metastatic nature of the liver lesions was determined on
the basis of progression or remission through imaging
after chemotherapy or endocrine therapy. Four experi-
enced radiologists, blinded to any other imaging data,
performed the B-mode and SEUS scanning using an
Aplio-400 (Toshiba, Tokyo, Japan). The Aplio-400 PVT-
375BT Transducer/Probe had been used with a 3.5 MHz
center frequency. Adverse events occurring up to 24 h
post injection were recorded according to Common Ter-
minology Criteria for Adverse Events (CTCAE version
4.0). The patients received a bolus intravenous injection
of Sonazoid (0.015 mL/kg body weight) through a
peripheral venous line, followed by 10 mL of normal
saline flush. After the administration of Sonazoid, the
portal veins, hepatic veins, and normal liver parenchyma
were uniformly enhanced immediately (vascular phase
image). Approximately 10 min after the injection, the
liver was scanned again to observe the post-vascular
image (Kupffer image). The hepatic metastases were
identified as perfusion defects (Fig. 1a) clearly more
visible in the post-vascular image than those in the
B-mode US (Fig. 1c) or early vascular phase (Fig. 1b)
including images of the arterial phase and the portal
phase, which were captured less than 10 min after So-
nazoid injection. The post-vascular phase image (Kupffer
image) lasted at least for 20 min.
A total of 24 patients underwent SEUS in addition to
B-mode US. The number and size of the metastases
identified through CECT and/or MR were compared with
those detected using B-mode US and SEUS. In SEUS, if a
lesion showed reduced enhancement (defect/washout),
then it was considered metastatic (Fig. 1) and if it showed
iso- or hyper-enhancement, then the lesion was considered
benign (Fig. 2), compared with the surrounding liver in
the post-vascular phase. Hepatic metastases were identi-
fied in most cases as perfusion defects in the post-vascular
phase image, and this image lasted 10–30 min after the
injection of Sonazoid, and in some cases, showed hypo-
echoic changes with rim enhancement, which also dis-
tinguished metastases from most other masses. Based on
baseline ultrasonography, metastases were defined as
clearly visible round, oval, or lobulated solid focal lesions
that were neither simple cysts nor typical of hemangioma,
focal fatty sparing or change. In SEUS, metastases were
defined as sharply marginated round, oval, or lobulated
hypoechoic defects in enhancing parenchyma in the portal
venous or post-vascular phase (Kupffer phase). Further,
tumor vessels and tumor enhancement of liver metastases
were visualized immediately in the early vascular phase
(arterial phase) following Sonazoid administration. How-
ever, not only relatively large vessels including tumor
Fig. 1 More hepatic metastases (arrows) were identified as perfusion defects (a) in the post-vascular phase (Kupffer phase) than at the early
vascular phase (b) or before the administration of Sonazoid using conventional B-mode US (c)
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vessels and portal veins, but also microvessels within the
liver parenchyma are rapidly fulfilled with Sonazoid mi-
crobubbles, which in turn permit rapid enhancement of
the tumor and liver parenchyma simultaneously. For each
patient, the final number of hepatic metastases present at
the time of US and SEUS was determined based on a
consensus reading, including the results of MR imaging
examination or CECT, US, SEUS, and follow-up imaging
examinations.
Statistics analysis
The standard was determined as the number of metastases
revealed through a combination of CECT or MRI and fol-
low-up. The sensitivity and accuracy of both types of US for
metastases were calculated in the detection of individual
metastases for each patient, and the sensitivities were
compared using the Wilcoxon signed rank test. A p value of
less than 0.05 was considered statistically significant.
Fig. 2 In SEUS, lesions showing iso-enhancement as a hemangioma (upper) and iso- or hyper-enhancement as a focal fatty change/sparing
(below) were considered benign (arrows)




All twenty-four patients with suspected hepatic metastatic
tumors (Table 1) received at least twice Sonazoid injec-
tions in each examination, and no general or cardiovascular
complications or severe adverse events were observed
during the procedure. Only one patient complained of mild
nausea (Grade 1) and a skin reaction (Grade1) on the
injected site after Sonazoid administration.
Follow-up examinations were performed every
3 months, and equivocal lesions under B-mode US and
SEUS were clarified through computed tomography (CT)
scan and/or magnetic resonance imaging (MRI). The
median follow-up was 14.1 months (range 9–28.2 months).
The total number of suspected metastatic lesions upon
initial examination was 84. A total of 19 patients presented
hepatic metastases, detected as a total of 79 metastatic
lesions using contrast-enhanced MRI and/or CECT; no
metastases were observed in 5 patients. A total of 74 hepatic
metastases were observed in 19 patients using CECT. Four
lesionswere observed using SEUS, but not withCECT; these
lesions were revealed as small metastases (4–14 mm at the
time of the diagnosis) upon follow-up imaging, showing an
increase in lesion size (Fig. 3). Therewas no exclusion based
on poor ultrasonographic conditions, and the population
included a total of 79 hepaticmetastases in 19 patients. SEUS
revealed 78 out of 79 metastases with tumor sizes ranging
from 4 to 174 mm in diameter. One lesion was missed using
both US and SEUS detection methods compared with the
MRI findings; this subdiaphragmatic lesion was not acces-
sible to ultrasonography. SEUS showed more MRI-con-
firmed metastatic lesions, detecting 83 of the 84 lesions with
98.8 % sensitivity, compared with conventional US, which
only detected 56 lesions in 11 of the 19 patients, with 66.7 %
sensitivity. SEUS and conventional US revealed suspected
malignant breast cancer metastases in a total of 78 and 51
Fig. 3 Four lesions were observed with SEUS (below arrows) but not with CECT (upper). Three of the four lesions were shown to be small
metastases (4–13 mm at the time of the diagnosis) during follow-up imaging, reflecting the increase in lesion size
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lesions, respectively, and the true positive rates (accuracy)
were 98.7 % (78/79) and 64.6 % (51/79), respectively
(Wilcoxon signed rank test p = 0.0009) (Table 2).
The mean maximum diameter of the lesions was 32 mm
(range 4–174 mm). The lesions missed using B-mode US
and detected with SEUS had a median maximum diameter
of 14 mm, ranging from 4 to 17 mm (Fig. 4). The average
sensitivity for the detection of individual metastases
improved significantly from 66.7 to 98.8 % (Wilcoxon
signed rank test p = 0.0112). False-positive results were
identified in five lesions in five different patients using
conventional B-mode US; three lesions were hepatic he-
mangiomas and two lesions were focal fatty change/spar-
ing (Fig. 2), diagnosed through SEUS, CECT and
confirmed upon follow-up imaging. No false-positives
results were observed with SEUS. However, four lesions
were missed under CECT scan examination and detected
only through SEUS, likely reflecting the small size of the
lesion, with a diameter of less than 13 mm (Fig. 3). Only
one patient, showing false negative rates using SEUS (also
on B-mode US), presented a subdiaphragmatic lesion that
was not typically accessible to ultrasonography. Large
metastatic lesions were markedly enhanced in the post-
vascular phase (Kupffer phase), either homogeneously or
peripherally. In the post-vascular phase, the liver metasta-
ses in breast cancer patients showed hypoenhancing or
perfusion defects in 65 of 79 lesions (82.3 %) (Fig. 5), in
contrast, fourteen of the 79 lesions (17.7 %) displayed
hypoechoic changes with rim enhancement (Fig. 6).
Discussion
In the present study, we demonstrated that liver metastasis
from breast cancer frequently shows hypoechoic defects
under contrast Sonazoid-enhanced US compared with the
surrounding normal liver parenchyma enhanced through
increased echogenicity resulting from treatment with a
Sonazoid microbubble contrast enhancer (Fig. 1).
Small liver metastases from breast cancer were only
detected through contrast Sonazoid-enhanced US, and
conventional US did not show abnormality in metastatic
lesions ranging from 4 to 17 mm in diameter. Similarly,
CECT did not detect micrometastatic lesions of less than
13 mm in diameter. In contrast, SEUS at the post-vascular
phase (Kupffer imaging) revealed 4–17 mm rounded small
hepatic metastatic lesions (Figs. 3 and 4), compared with
CECT scan showed a low sensitivity for detection and
characterization of lesions smaller than 1 cm [17]; con-
trast-enhanced US had detected small hepatic metastatic
lesions (\1 cm) with a high sensitivity [18]; and in this
study, four additional small lesions had been revealed by
SEUS, but not by CECT. These results suggest SEUS has
better contrast resolution than CECT for detecting small
hepatic metastatic lesions, and SEUS may improve the
detection of miliary metastases (0.5–1 cm) [19].
The detection of large liver metastases from breast
cancer using conventional B-mode US and SEUS in the
post-vascular phase, revealed that 82.3 % of most
enhanced lesions showed reduced enhancement (defect/
washout) (Fig. 5), and 17.7 % of the lesions showed
hypoechoic changes with rim enhancement in the post-
vascular phase using SEUS, which was not visible through
baseline ultrasound (Fig. 6).
In the present study, contrast Sonazoid-enhanced US
showed higher sensitivity and accuracy for the detection of
liver metastases from breast cancer compared with con-
ventional unenhanced B-mode US. Several clinical trials
involving contrast-enhanced US using Sonazoid to detect
hepatic metastasis have been performed worldwide in
Table 2 Results of Sonazoid-
enhanced ultrasonography for
patients with hepatic metastasis
of breast cancer
a 24 patients with total 84
hepatic tumors having or
suspected of having metastatic
cancer from breast cancer
b 19 patients with a total 79





B-mode Sonazoid CECT MRI B-mode Sonazoid
No. false
positive cases
Total lesions of suspected metastasesa 84 84 84 84
Total detected lesion 56 83 80 84
Total lesions of MBCb 79 79 79 79
Detected No. MBC 51 78 75 79
Detected No. other diseases 5 0
Hemangioma 0 3 3 3 3 0
Focal fatty change 0 2 2 2 2 0
Sensitivity (%)c 66.7 98.8 95.2 100
Accuracy (%)c 64.6 98.7 94.9 100
Positive predictive rate (%) 70.9 98.7
False positive rate (%) 6.3 0
False negative rate (%) 29.1 1.3
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various cancers [9, 20–22] and these previous studies have
also demonstrated the improvement in accuracy of con-
trast-enhanced US in diagnosing hepatic metastasis [23–
25]. Differential diagnosis of hepatic metastasis between
breast cancer and other original cancer may indeed be a
problem, there were some reports demonstrating that
hepatic cellular carcinoma shows increased enhancement
in the arterial phase, metastasis from gastrointestinal
Fig. 4 The lesions missed with US and detected with SEUS (white arrows) ranged in size from 4 to 17 mm, with an average maximum diameter
of 14 mm
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cancer and neuroendocrine tumor can be identified with the
hypoenhancement in the portal venous and the post-vas-
cular phase [22]. However, as far as we know, no published
study has specifically reported the value of SEUS for
detecting hepatic liver metastases from breast cancers.
Contrast-enhanced ultrasound with Sonazoid detected
significantly more metastases compared with conventional
US, with a sensitivity of 98.8 versus 66.7 %. However,
SEUS revealed no additional patients with metastatic dis-
ease. The hepatic metastases detected through SEUS were
indeed relatively small lesions (4–17 mm), often associated
with larger lesions. The detection of hepatic metastases
from breast cancer using conventional US is limited by the
relatively small difference in background patterns between
the lesions and hepatic parenchyma, resulting in poor
contrast differentiation between the two tissues, likely
reflecting the difficulty in definitively diagnosing liver
hemangioma and focal fatty change/sparing lesions using
only B-mode US. The use of an ultrasound contrast agent
such as Sonazoid increases the echogenicity of the liver at
the post-vascular specific phase as the microbubbles
accumulate in the normal parenchyma.
Although we did not specifically compare the value of
the different vascular phases in the detection of metastases
from breast and other cancers, the post-vascular phase
image (Kupffer image) was valuable, as 83.3 % of the
metastases from breast cancer were perfusion defects in the
parenchyma, and 17.7 % of breast cancer metastases was
iso- or hypoechoic compared with liver parenchyma,
showing hypoechoic changes with rim enhancement in the
post-vascular phase. However, we did not confirm this
finding quantitatively because only 14 of the 79 lesions
detected showed central necrotic hypoechoic changes.
Notably, the internal content of the metastatic lesions or the
areas showing necrotic changes were also correctly iden-
tified using SEUS. Because the data from the 19 patients
subjected to CECT was limited, the difference between
SEUS and CECT scan imaging was not significant in this
study. Four lesions were missed by dynamic CT scan
examination, but these lesions were identified using SEUS,
likely reflecting the small size of the lesion. However, one
patient, who showed false-negative results after both
baseline B-mode and SEUS, had a subdiaphragmatic lesion
that was not accessible to sonography. The limitations of
dynamic CT scanning make it difficult to detect small
metastases, and the limitations of US make it difficult to
visualize subdiaphragmatic lesions.
Furthermore, ultrasound contrast agents, including So-
nazoid modify the basic physical interactions between
ultrasound waves and hepatic tissues and amplify the signal
Fig. 5 Approximately 82.3 % of the liver metastases of breast cancer showed hypoenhancing or filling defects (white arrows) in the post-
vascular phase
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produced by flowing blood. Thus, Sonazoid might be
useful for detecting subtle flow abnormalities and distin-
guishing areas of abnormal flow relative to normal back-
ground parenchymal perfusion. As a result, these contrast
agents might improve the characterization of focal liver
lesions compared with standard B-mode US, while pro-
viding complementary information with other imaging
modalities [26–28]. In the present study, we also demon-
strated using contrast Sonazoid-enhanced US for the ade-
quate detection of benign lesions, including three hepatic
hemangiomas and two focal fatty changes, in patients with
metastatic breast cancer.
Thus, these results suggest that SEUS, followed by
conventional B-mode US for evaluating breast cancer
metastases, might not only be used to successfully detect
malignant lesions with higher sensitivity and accuracy, but
also to identify benign lesions, including hepatic heman-
gioma or focal fatty changes, for the differential diagnosis
of hepatic lesions. Moreover, because it is competitive, cost
effective and less invasive, SEUS technique used for
Fig. 6 Approximately 17.7 % of the liver metastases of breast cancer displayed hypoechoic changes with rim enhancement in the post-vascular
phase
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follow-up of hepatic metastases from breast cancer may be
an alternative to other imaging modalities including CT
scan and MRI. Consequently, the development of a new
SEUS approach could improve the diagnostic sensitivity
and detection accuracy for hepatic breast cancer metastases
and could also provide important information for making
treatment decisions for patients with breast cancer.
These results were presented at the 72nd Annual
Meeting of the Japanese Breast Cancer Society in June
2013.
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